Boehringer Ingelheim Aggrenox
Executive Summary
Dipyridimole and aspirin twice-daily capsules are deemed "approvable" June 15. Extended-release combination was recommended by an FDA advisory committee for reduction in risk of a secondary stroke, but not for reduction of mortality risk (1"The Pink Sheet" May 3, p. 9)
You may also be interested in...
BI Aggrenox Recommended For Stroke; Mortality Labeling Uncertain
FDA will consider whether to include information on the potential mortality benefit of Boehringer-Ingelheim's Aggrenox (dipyridamole/aspirin) in labeling after an advisory committee recommended against including a mortality claim among the approved indications for the product.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials